Table 1.
List of included studies
| Condition | PI | PY | Study design | Phase | Enrolled patients | Dose (mg/daily) |
|---|---|---|---|---|---|---|
| DTC | Cabanillas | 2014 | Clinical Trial | I | 15 | 140 |
| DTC | Shah | 2015 | Clinical Trial | II | 25 | 60 or 80 (if tolerated) |
| DTC | Konda | 2017 | Prospective analysis on clinical trial | II | 25 | 60 or 80 (if tolerated) |
| DTC | Brose | 2021 | Clinical Trial | III | 187 | 60 |
| DTC | Taylor | 2022 | Clinical Trial | Ib | 102 | 40 or 60 (plus atezolizumab) |
| MTC | Elisei | 2013 | Clinical Trial | III | 330 | 140 |
| MTC | Bentzien | 2013 | Preclinical | preclinical | biochemical assays/mice model | N/A |
| MTC | Rinciog | 2014 | Adjusted indirect comparison | indirect comparison | N/A | N/A |
| MTC | Sherman | 2016 | Correlative analysis | indirect comparison | 330 | 140 |
| MTC | Schlumberger | 2017 | Clinical Trial | III | 330 | 140 |
| MTC | Koehler | 2021 | Real World Comparative Study | N/A | 48 | N/A |
| MTC | Capdevila | 2022 | Clinical Trial | IV | 247 | 60 vs 140 |
| MTC (+ other cancers) | Kurzrock | 2011 | Clinical Trial | I | 37, (85) | MTD (175) |
| MCC | Rabinowits | 2018 | Clinical Trial | II | 8 | 60 (40 or 20 if not tolerated) |
| MCC | Tarabadkar | 2018 | Case Series | N/A | 5 | 60 reduced to 40 |
| PPGL | Roman | 2017 | Review | N/A | N/A | N/A |
| PPGL | Jimenez | 2018 | Expert Opinion | N/A | N/A | N/A |
| PPGL | Economides | 2020 | Case Report | N/A | 1 | 60/40 |
| GU Tract Tumours | Apolo | 2020 | Clinical Trial | I | 54 | 40 |
| ACC | Phan | 2015 | Preclinical | N/A | biochemical assays/mice model | N/A |
| ACC | Kroiss | 2020 | Retrospective cohort study | N/A | 16 | 60/100/140/20 |
| ACC | Miller | 2020 | Retrospective cohort study | N/A | 15 | N/A |
| NEN | Sennino | 2012 | Preclinical | preclinical | biochemical assays/mice model | N/A |
| NEN | Reuther | 2016 | Preclinical | preclinical | biochemical assays/mice model | N/A |
| NEN | Chan | 2018 | Clinical Trial | II | 35 | 60 |
| NEN | Grillo | 2018 | Review | N/A | N/A | N/A |
PI Principal Investigator, PY Publication Year, DTC Differentiated Thyroid Cancer, MTC Medullary Thyroid Carcinoma, MCC Merkel Cell Carcinoma, PPGL Pheochromocytoma and Paraganglioma, GU genitourinary, ACC Adrenocortical Carcinoma, NEN Neuroendocrine Neoplasm, N/A not applicable, MTD maximum tolerated dose